Straits Times Index
3,307.52 +4.33 (+0.13%) Nikkei
38,641.74 +405.67 (+1.06%) Hang Seng
18,508.48 -69.82 (-0.38%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,688.51 -421.23 (-0.66%) CMC Crypto 200
1,373.06 +60.44 (+4.61%)
VRTX Jan 2025 230.000 call
- Reuters
UPDATE 1-Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments
Vertex Pharmaceuticals beat Wall Street estimates for first-quarter profit on Monday, driven by robust uptake for its blockbuster cystic fibrosis treatments. Cystic fibrosis (CF) - an inherited disorder that causes severe damage to the lungs, digestive system and other organs - affects an estimated 105,000 people across 94 countries, according to data from U.S.-based CF Foundation. Vertex reported adjusted earnings per share of $4.76 on revenue of $2.69 billion, topping market estimates $4.06 on revenue of $2.58 billion, according to LSEG data, for the quarter ended March 31.
- GuruFocus.com
Vertex Pharmaceuticals Q1 2024 Earnings: Surpasses Revenue Expectations with Strategic Expansions
Comprehensive Analysis of Vertex Pharmaceuticals' Financial Performance and Strategic Initiatives
- Zacks
Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Top Estimates
Vertex (VRTX) delivered earnings and revenue surprises of 16.10% and 5.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
